318 related articles for article (PubMed ID: 25933688)
41. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
[TBL] [Abstract][Full Text] [Related]
42. Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation.
Leiser D; Pochon B; Blank-Liss W; Francica P; Glück AA; Aebersold DM; Zimmer Y; Medová M
FEBS Lett; 2014 Mar; 588(5):653-8. PubMed ID: 24440350
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
44. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
45. The novel kinase inhibitor EMD1214063 is effective against neuroblastoma.
Scorsone K; Zhang L; Woodfield SE; Hicks J; Zage PE
Invest New Drugs; 2014 Oct; 32(5):815-24. PubMed ID: 24832869
[TBL] [Abstract][Full Text] [Related]
46. ERK inhibition overcomes acquired resistance to MEK inhibitors.
Hatzivassiliou G; Liu B; O'Brien C; Spoerke JM; Hoeflich KP; Haverty PM; Soriano R; Forrest WF; Heldens S; Chen H; Toy K; Ha C; Zhou W; Song K; Friedman LS; Amler LC; Hampton GM; Moffat J; Belvin M; Lackner MR
Mol Cancer Ther; 2012 May; 11(5):1143-54. PubMed ID: 22402123
[TBL] [Abstract][Full Text] [Related]
47. Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven models.
Poliaková M; Felser A; Pierzchala K; Nuoffer JM; Aebersold DM; Zimmer Y; Zamboni N; Medová M
FEBS J; 2019 Jul; 286(14):2692-2710. PubMed ID: 30993872
[TBL] [Abstract][Full Text] [Related]
48. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells.
Lee S; Heinrich EL; Lu J; Lee W; Choi AH; Luu C; Chung V; Fakih M; Kim J
Pancreas; 2016 Feb; 45(2):286-92. PubMed ID: 26262587
[TBL] [Abstract][Full Text] [Related]
49. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
50. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
[TBL] [Abstract][Full Text] [Related]
51. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
Matsubara D; Ishikawa S; Oguni S; Aburatani H; Fukayama M; Niki T
J Thorac Oncol; 2010 Sep; 5(9):1317-24. PubMed ID: 20736805
[TBL] [Abstract][Full Text] [Related]
52. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
[TBL] [Abstract][Full Text] [Related]
53. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
[TBL] [Abstract][Full Text] [Related]
54. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition.
Cagnol S; Rivard N
Oncogene; 2013 Jan; 32(5):564-76. PubMed ID: 22430215
[TBL] [Abstract][Full Text] [Related]
55. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines.
Stolze B; Reinhart S; Bulllinger L; Fröhling S; Scholl C
Sci Rep; 2015 Feb; 5():8535. PubMed ID: 25705018
[TBL] [Abstract][Full Text] [Related]
56. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
[TBL] [Abstract][Full Text] [Related]
57. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631
[TBL] [Abstract][Full Text] [Related]
58. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Hofmann MH; Gmachl M; Ramharter J; Savarese F; Gerlach D; Marszalek JR; Sanderson MP; Kessler D; Trapani F; Arnhof H; Rumpel K; Botesteanu DA; Ettmayer P; Gerstberger T; Kofink C; Wunberg T; Zoephel A; Fu SC; Teh JL; Böttcher J; Pototschnig N; Schachinger F; Schipany K; Lieb S; Vellano CP; O'Connell JC; Mendes RL; Moll J; Petronczki M; Heffernan TP; Pearson M; McConnell DB; Kraut N
Cancer Discov; 2021 Jan; 11(1):142-157. PubMed ID: 32816843
[No Abstract] [Full Text] [Related]
59. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
60. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
